-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Kymera Therapeutics, Raises Price Target to $125

Benzinga·12/10/2025 15:58:42
Listen to the news
JP Morgan analyst Brian Cheng maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $70 to $125.